{
 "as_of": "2026-11-11",
 "cmr": "se-cm-kg/XSTO/SE0002148817",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Hansa Biopharma AB (Nasdaq Stockholm: SE0002148817) — research page\n\nAs of 2026-11-11 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Hansa Biopharma AB, listed on Nasdaq Stockholm, with ticker SE0002148817 and ISIN SE0002148817, and LEI 549300LLEO25ZJJ3NT91. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 112 filings in the twelve months to 2026-11-11, across 53 filing days. The median gap between filing days is 5.0 days, against a median of 9.5 days for the 398 issuers on Nasdaq Stockholm. The median filing count for the exchange is 30.0. The latest filing is dated 2026-11-11 and is of type Interim report (Q1 and Q3), and the days from latest filing to record date are 0, against an exchange median of 7.0 days. The sector median is not on the record.\n\n## Auditor\n\nThe auditor of record and its location are not on the record. Auditor changes are not on the record, as the lifecycle type map for this register is not yet available.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as the index does not carry a lifecycle type for this register. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe orderability outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names nine research houses on the issuer's investor-relations page: SEB, ABG Sundal Collier, Van Lanschot Kempen, Carnegie, H.C. Wainwright & Co., William Blair, Leerink Partners LLC, Jefferies LLC and Wedbush Securities.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0002148817 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.hansabiopharma.com/investors/analysts/ (coverage)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0002148817 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-11",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0002148817",
  "coverage": {
   "count": 9,
   "houses": [
    {
     "analyst": "Christopher Uhde",
     "house": "SEB",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Alexander Krämer",
     "house": "ABG Sundal Collier",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Chiara Montironi",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Erik Hultgård",
     "house": "Carnegie",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Douglas Tsao",
     "house": "H.C. Wainwright & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Matt Phipps",
     "house": "William Blair",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Thomas J. Smith",
     "house": "Leerink Partners LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "Q4 2025",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Farzin Haque, Ph.D.",
     "house": "Jefferies LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "Q4 2025",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "David Nierengarten, Ph.D.",
     "house": "Wedbush Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.hansabiopharma.com/investors/analysts/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.hansabiopharma.com/investors/analysts/",
     "result": "read: 9 of 18 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "stated per house where the page states it",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 2,
    "Changes board/management/auditors": 2,
    "Decisions of general meeting": 4,
    "Financial Statement Release": 2,
    "Half Year financial report": 2,
    "Inside information": 18,
    "Interim report (Q1 and Q3)": 4,
    "Investor News": 74,
    "Notice to general meeting": 4
   },
   "cadence_median_gap_days": 5,
   "filing_days": 53,
   "filings": 112,
   "latency_days": 0,
   "latest": [
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-11",
     "source": "https://view.news.eu.nasdaq.com/view?id=bb429445faccbd0a5cc72cdd84b3c8e90&lang=en&src=listed",
     "title": "Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-11",
     "source": "https://view.news.eu.nasdaq.com/view?id=b79efda60f4faa3e16de4fce1414de12f&lang=sv&src=listed",
     "title": "Hansa Biopharma rapporterar finansiella resultat för tredje kvartalet och delårsperioden 2026",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Investor News",
     "date": "2026-11-10",
     "source": "https://view.news.eu.nasdaq.com/view?id=beafff320f9a633af2ce0eb2dab66ab68&lang=sv&src=listed",
     "title": "Hansa Biopharma deltar i Jefferies Global Healthcare Conference i London",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-11-10",
     "source": "https://view.news.eu.nasdaq.com/view?id=b486be8d8df61e410f4f20218fe820a4f&lang=en&src=listed",
     "title": "Hansa Biopharma to participate in Jefferies Global Healthcare Conference in London",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b922ad51d3837cde27ffe4013e87af4d6&lang=sv&src=listed",
     "title": "Hansa Biopharma presenterar vid Stifel 2026 Healthcare Conference",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-11",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0002148817",
   "window": {
    "from": "2025-11-11",
    "to": "2026-11-11"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0002148817"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-12",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0002148817)",
    "state": "sourced",
    "value": "549300LLEO25ZJJ3NT91"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Hansa Biopharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0002148817"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:91b9cc6af246b0787cd4aebf1d4f9e9c37936506feab5f19f8f589fe1ce12d37",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-11",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0002148817",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-12",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:91b9cc6af246b0787cd4aebf1d4f9e9c37936506feab5f19f8f589fe1ce12d37",
 "path": "/se/XSTO/SE0002148817",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Hansa Biopharma AB, listed on Nasdaq Stockholm, with ticker SE0002148817 and ISIN SE0002148817, and LEI 549300LLEO25ZJJ3NT91. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 112 filings in the twelve months to 2026-11-11, across 53 filing days. The median gap between filing days is 5.0 days, against a median of 9.5 days for the 398 issuers on Nasdaq Stockholm. The median filing count for the exchange is 30.0. The latest filing is dated 2026-11-11 and is of type Interim report (Q1 and Q3), and the days from latest filing to record date are 0, against an exchange median of 7.0 days. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record and its location are not on the record. Auditor changes are not on the record, as the lifecycle type map for this register is not yet available.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as the index does not carry a lifecycle type for this register. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The orderability outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names nine research houses on the issuer's investor-relations page: SEB, ABG Sundal Collier, Van Lanschot Kempen, Carnegie, H.C. Wainwright & Co., William Blair, Leerink Partners LLC, Jefferies LLC and Wedbush Securities.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0002148817"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.hansabiopharma.com/investors/analysts/"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0002148817"
  }
 ],
 "title": "Hansa Biopharma AB (SE0002148817) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}